|
gptkbp:instanceOf
|
gptkb:Cannabis
|
|
gptkbp:aroma
|
odorless
|
|
gptkbp:biosynthesized_from
|
from cannabigerolic acid (CBGA)
|
|
gptkbp:boilingPoint
|
175–178 °C
|
|
gptkbp:CASNumber
|
5957-75-5
|
|
gptkbp:chemicalFormula
|
C21H30O2
|
|
gptkbp:color
|
colorless to pale amber solid
|
|
gptkbp:DEAStatus
|
Schedule I (if synthetic, US federal)
|
|
gptkbp:eliminationHalfLife
|
gptkb:unknown
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:FDAWarning
|
not evaluated for safety or efficacy
|
|
gptkbp:firstIsolatedFrom
|
1941
|
|
gptkbp:firstSynthesized
|
gptkb:Roger_Adams
|
|
gptkbp:flavor
|
slightly bitter
|
|
gptkbp:foundIn
|
gptkb:Cannabis
|
|
gptkbp:isomerOf
|
delta-9-THC
|
|
gptkbp:IUPACName
|
gptkb:(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol
|
|
gptkbp:legalStatus
|
varies by country and US state
|
|
gptkbp:marketedAs
|
hemp-derived product
legal alternative to delta-9-THC
|
|
gptkbp:meltingPoint
|
63–66 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
314.464 g/mol
|
|
gptkbp:otherName
|
gptkb:Δ8-THC
delta-8-tetrahydrocannabinol
Δ8-tetrahydrocannabinol
|
|
gptkbp:produces
|
red eyes
altered perception
dry mouth
appetite stimulation
mild euphoria
anxiety (rare)
|
|
gptkbp:psychoactive
|
true
|
|
gptkbp:relatedTo
|
gptkb:THCV
gptkb:CBD
gptkb:CBN
delta-9-THC
|
|
gptkbp:riskFactor
|
contaminants in unregulated products
possible psychoactive impairment
unknown long-term effects
|
|
gptkbp:routeOfAdministration
|
oral
inhalation
sublingual
|
|
gptkbp:solubility
|
lipid-soluble
|
|
gptkbp:source
|
can be synthesized from CBD
minor constituent in cannabis
|
|
gptkbp:usedFor
|
recreational purposes
potential medical uses
|
|
gptkbp:bfsParent
|
gptkb:tetrahydrocannabinol
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
delta-8-THC
|